PMID- 37024061
OWN - NLM
STAT- MEDLINE
DCOM- 20230522
LR  - 20230522
IS  - 1873-2968 (Electronic)
IS  - 0006-2952 (Linking)
VI  - 212
DP  - 2023 Jun
TI  - The role of exosomes in the stemness maintenance and progression of acute myeloid 
      leukemia.
PG  - 115539
LID - S0006-2952(23)00130-2 [pii]
LID - 10.1016/j.bcp.2023.115539 [doi]
AB  - Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic 
      cells, which is characterized by the aberrant clonal proliferation of immature 
      myeloblasts and compromised hematopoiesis. The leukemic cell population is 
      strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell 
      subset with stemness characteristics and self-renewal ability, which contribute 
      to the development of refractory or relapsed AML. It is now acknowledged that 
      LSCs develop from hematopoietic stem cells (HSCs) or phenotypically directed cell 
      populations with transcriptional stemness characteristics under selective 
      pressure from the bone marrow (BM) niche. Exosomes are extracellular vesicles 
      containing bioactive substances involved in intercellular communication and 
      material exchange under steady state and pathological conditions. Several studies 
      have reported that exosomes mediate molecular crosstalk between LSCs, leukemic 
      blasts, and stromal cells in the BM niche, promoting LSC maintenance and AML 
      progression. This review briefly describes the process of LSC transformation and 
      the biogenesis of exosomes, highlighting the role of leukemic-cell- and 
      BM-niche-derived exosomes in the maintenance of LSCs and AML progression. In 
      addition, we discuss the potential application of exosomes in the clinic as 
      biomarkers, therapeutic targets, and carriers for targeted drug delivery.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Li, Qian
AU  - Li Q
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China.
FAU - Wang, Mengyuan
AU  - Wang M
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China.
FAU - Liu, Lingbo
AU  - Liu L
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China. Electronic address: 
      liulingbo@hust.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230404
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Biomarkers)
SB  - IM
MH  - Humans
MH  - *Exosomes
MH  - *Leukemia, Myeloid, Acute/pathology
MH  - Hematopoietic Stem Cells/pathology
MH  - Hematopoiesis
MH  - Biomarkers
MH  - Neoplastic Stem Cells/pathology
OTO - NOTNLM
OT  - Acute myeloid leukemia
OT  - Bone marrow niche
OT  - Drug resistance
OT  - Exosomes
OT  - Leukemic stem cells
OT  - Stemness maintenance
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/04/07 06:00
MHDA- 2023/05/22 06:42
CRDT- 2023/04/06 19:28
PHST- 2023/01/30 00:00 [received]
PHST- 2023/03/17 00:00 [revised]
PHST- 2023/03/29 00:00 [accepted]
PHST- 2023/05/22 06:42 [medline]
PHST- 2023/04/07 06:00 [pubmed]
PHST- 2023/04/06 19:28 [entrez]
AID - S0006-2952(23)00130-2 [pii]
AID - 10.1016/j.bcp.2023.115539 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 2023 Jun;212:115539. doi: 10.1016/j.bcp.2023.115539. Epub 2023 
      Apr 4.